Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday

• click to rate

  Posted by Two Blokes Jun 26 - Filed in Stock - 2 views
  
  Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.